Thu. 8 Apr 2021, 1:34pm ETBenzinga
In: Press Releases

New York, New York--(Newsfile Corp. - April 8, 2021) - Levi & Korsinsky notifies investors that it has commenced an investigation of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ:FGEN) concerning possible violations of federal securities laws.

After the market closed on Apr. 6, 2021, FibroGen admitted that the primary cardiovascular safety analysis of its roxadustat Phase 3 program for the treatment of anemia of chronic kidney disease included post-hoc changes to the stratification factors. The analysis with the post-hoc stratification factors resulted in higher hazard ratios. The company ultimately admitted it now "cannot conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa."

On this news, FibroGen's stock price fell $14.90 per share, or 43%, to close at $19.74 per share on April 7, 2021. To obtain additional information, go to:

or contact Joseph E. Levi, Esq. either via email at or by telephone at (212) 363-7500.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.


Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171

To view the source version of this press release, please visit